Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms

PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub Read More

2024-03-25T10:21:40-04:00June 1st, 2014|Adjuvant, Evidence, MammaPrint, RASTER|

Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature

PUBLICATION: Eur J Cancer. 2014 Apr;50(6):1045-54. doi: 10.1016/j.ejca.2014.01.016. Epub 2014 Read More

2024-03-25T10:23:07-04:00April 1st, 2014|Adjuvant, Evidence, MammaPrint, RASTER|

Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience

PUBLICATION: Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3. Read More

2024-03-07T12:14:52-05:00August 1st, 2013|Adjuvant, Evidence, MammaPrint|

MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer

PUBLICATION: S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223. Read More

2024-03-25T10:45:11-04:00July 3rd, 2013|Adjuvant, Evidence, MammaPrint|
Go to Top